(LENZ) LENZ Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 301m USD | Total Return: -61% in 12m

Vision Therapies, Drug Development, Clinical Trials
Total Rating 20
Safety 66
Buy Signal -1.66
Biotechnology
Industry Rotation: -8.0
Market Cap: 301M
Avg Turnover: 11.4M USD
ATR: 9.39%
Peers RS (IBD): 0.1
Risk 5d forecast
Volatility91.4%
Rel. Tail Risk-19.2%
Reward TTM
Sharpe Ratio-0.63
Alpha-109.57
Character TTM
Beta1.604
Beta Downside-0.137
Drawdowns 3y
Max DD83.10%
CAGR/Max DD-0.22

Warnings

Altman Z'' -9.96 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: LENZ LENZ Therapeutics

LENZ Therapeutics Inc. is a biopharmaceutical company developing vision improvement therapies. Its primary focus is on presbyopia, a common age-related eye condition affecting near vision.

The companys lead product candidates, LNZ100 and LNZ101, are currently in Phase III clinical trials. Biopharmaceutical companies typically incur significant research and development costs as products advance through these trial phases.

Founded in 2013 and headquartered in Solana Beach, California, the company changed its name from Presbyopia Therapies, Inc. to LENZ Therapeutics, Inc. in June 2021. Understanding the competitive landscape and market potential for presbyopia treatments is crucial for investors, and further research on ValueRay can provide these insights.

Headlines to Watch Out For
  • Phase 3 clinical trial results for LNZ100 and LNZ101 impact stock
  • FDA approval timeline for presbyopia treatments creates volatility
  • Market adoption of new presbyopia therapies drives revenue
  • Competition from existing and emerging vision correction solutions
  • Biopharmaceutical research and development expenses affect profitability
Piotroski VR‑10 (Strict) 0.0
Net Income: -82.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.23 > 0.02 and ΔFCF/TA 4.92 > 1.0
NWC/Revenue: 1.42k% < 20% (prev 305k%; Δ -304k% < -1%)
CFO/TA -0.23 > 3% & CFO -69.2m > Net Income -82.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 13.80 > 1.5 & < 3
Outstanding Shares: last quarter (31.1m) vs 12m ago 13.02% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 7.32% > 50% (prev 0.03%; Δ 7.29% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -9.96
A: 0.89 (Total Current Assets 292.3m - Total Current Liabilities 21.2m) / Total Assets 305.9m
B: -0.74 (Retained Earnings -227.1m / Total Assets 305.9m)
C: -0.34 (EBIT TTM -89.1m / Avg Total Assets 260.6m)
D: -10.54 (Book Value of Equity -226.9m / Total Liabilities 21.5m)
Altman-Z'' Score: -9.96 = D
What is the price of LENZ shares? As of April 13, 2026, the stock is trading at USD 9.07 with a total of 516,287 shares traded.
Over the past week, the price has changed by -5.62%, over one month by -23.27%, over three months by -41.75% and over the past year by -60.97%.
Is LENZ a buy, sell or hold? LENZ Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy LENZ.
  • StrongBuy: 5
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the LENZ price?
Analysts Target Price 41.1 353.6%
LENZ Therapeutics (LENZ) - Fundamental Data Overview as of 08 April 2026
P/S = 15.7856
P/B = 1.0663
Revenue TTM = 19.1m USD
EBIT TTM = -89.1m USD
EBITDA TTM = -88.8m USD
Long Term Debt = 815k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 465k USD (from shortTermDebt, last quarter)
Debt = 1.28m USD (corrected: LT Debt 815k + ST Debt 465k)
Net Debt = -291.1m USD (recalculated: Debt 1.28m - CCE 292.3m)
Enterprise Value = 10.2m USD (301.3m + Debt 1.28m - CCE 292.3m)
 Interest Coverage Ratio = unknown (Ebit TTM -89.1m / Interest Expense TTM 0.0)
 EV/FCF = -0.15x (Enterprise Value 10.2m / FCF TTM -70.0m)
 FCF Yield = -683.0% (FCF TTM -70.0m / Enterprise Value 10.2m)
 FCF Margin = -366.7% (FCF TTM -70.0m / Revenue TTM 19.1m)
 Net Margin = -430.3% (Net Income TTM -82.1m / Revenue TTM 19.1m)
 Gross Margin = unknown ((Revenue TTM 19.1m - Cost of Revenue TTM 598k) / Revenue TTM)
 Tobins Q-Ratio = 0.03 (Enterprise Value 10.2m / Total Assets 305.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.28m)
Taxrate = 21.0% (US default 21%)
NOPAT = -70.4m (EBIT -89.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.80 (Total Current Assets 292.3m / Total Current Liabilities 21.2m)
Debt / Equity = 0.00 (Debt 1.28m / totalStockholderEquity, last quarter 284.3m)
 Debt / EBITDA = 3.28 (negative EBITDA) (Net Debt -291.1m / EBITDA -88.8m)
 Debt / FCF = 4.16 (negative FCF - burning cash) (Net Debt -291.1m / FCF TTM -70.0m)
 Total Stockholder Equity = 219.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.52% (Net Income -82.1m / Total Assets 305.9m)
RoE = -37.47% (Net Income TTM -82.1m / Total Stockholder Equity 219.2m)
RoCE = -40.49% (EBIT -89.1m / Capital Employed (Equity 219.2m + L.T.Debt 815k))
 RoIC = -32.10% (negative operating profit) (NOPAT -70.4m / Invested Capital 219.2m)
 WACC = 11.58% (E(301.3m)/V(302.6m) * Re(11.63%) + D(1.28m)/V(302.6m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 93.63%
 [DCF] Fair Price = unknown (Cash Flow -70.0m)
 EPS Correlation: 67.32 | EPS CAGR: 13.83% | SUE: -0.25 | # QB: 0
Revenue Correlation: 63.21 | Revenue CAGR: 26.40% | SUE: -0.14 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.94 | Chg7d=-0.244 | Chg30d=-0.244 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-12-31): EPS=-3.79 | Chg7d=-0.799 | Chg30d=-0.799 | Revisions Net=-2 | Growth EPS=-33.0% | Growth Revenue=+48.4%
EPS next Year (2027-12-31): EPS=-2.63 | Chg7d=-1.806 | Chg30d=-1.806 | Revisions Net=-2 | Growth EPS=+30.5% | Growth Revenue=+198.3%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle